Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
Biondini M, Kiepas A, El-Houjeiri L, Annis MG, Hsu BE, Fortier AM, Morin G, Martina JA, Sirois I, Aguilar-Mahecha A, Gruosso T, McGuirk S, Rose AAN, Tokat UM, Johnson RM, Sahin O, Bareke E, St-Pierre J, Park M, Basik M, Majewski J, Puertollano R, Pause A, Huang S, Keler T, Siegel PM. Biondini M, et al. Among authors: tokat um. Oncogene. 2022 Mar;41(12):1701-1717. doi: 10.1038/s41388-022-02206-z. Epub 2022 Feb 2. Oncogene. 2022. PMID: 35110681
Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U, Ersan PG, Tokat ÜM, Eyüpoğlu E, Saatci Ö, Jandaghi P, Wiemann S, Üner A, Cekic C, Riazalhosseini Y, Şahin Ö. Mishra RR, et al. Among authors: tokat um. Clin Cancer Res. 2018 Apr 15;24(8):1987-2001. doi: 10.1158/1078-0432.CCR-17-2776. Epub 2018 Jan 31. Clin Cancer Res. 2018. PMID: 29386221
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.
Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, Sikirzhytski V, Tokat UM, Aykut G, Ansari SA, Dogan HT, Dogan M, Jandaghi P, Isik A, Gundogdu F, Kosemehmetoglu K, Dizdar O, Aksoy S, Akyol A, Uner A, Buckhaults PJ, Riazalhosseini Y, Sahin O. Saatci O, et al. Among authors: tokat um. Nat Commun. 2020 May 15;11(1):2416. doi: 10.1038/s41467-020-16199-4. Nat Commun. 2020. PMID: 32415208 Free PMC article.
Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations.
Aydın E, Tokat ÜM, Özgü E, Adibi A, Tutar O, Kurzrock R, Demiray M. Aydın E, et al. Among authors: tokat um. Ther Adv Med Oncol. 2024 Apr 18;16:17588359241247023. doi: 10.1177/17588359241247023. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38645422 Free PMC article.
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Cetin M, Tokat UM, Gedik ME, Bal H, Sahin OS, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O. Saatci O, et al. Among authors: tokat um. bioRxiv [Preprint]. 2023 Nov 5:2023.11.05.565697. doi: 10.1101/2023.11.05.565697. bioRxiv. 2023. PMID: 38496603 Free PMC article. Preprint.
11 results